Charles River Laboratories Intl. Inc vs Paychex, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $298.76 (market cap $14.23B), while Paychex, Inc. trades at $104.42 (market cap $37.19B). The key difference: Paychex, Inc. is far larger — about 2.6× Charles River Laboratories Intl. Inc's market cap, and Paychex, Inc. pays a 4.56% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Paychex, Inc. for 56 Days on average.
| CRL | PAYX | |
|---|---|---|
Market Cap | $14.23B | $37.19B |
Volume | 1,176,885 | 3,344,316 |
Sector | Health | Industrials |
52-Week High | $310.77 | $128.59 |
52-Week Low | $149.93 | $85.57 |
Typical Hold Time | 33 Days | 56 Days |
Enterprise Value | $17.06B | $40.87B |
Dividend Yield | — | 4.56% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
Paychex (PAYX) trades at $101.55, up 0.52% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 27.35% net income margin and 47.06% ROE, but valuation ratios like P/E of 20.73 and P/S of 5.67 appear elevated. Recent news highlights mixed sentiment, with earnings outperformance offset by concerns over dividend sustainability and labor market cooling.
The outlook is cautious; while fundamentals remain solid with consistent revenue growth, high debt levels and bearish technicals pose risks. Analyst consensus leans hold with a $111 price target, suggesting limited upside. Key opportunities include dividend yield and PEO growth, but investors face headwinds from economic sensitivity and competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →